Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. following a significant drop in its stock price after the FDA rejected its drug application for RP1, intended for advanced melanoma treatment [1][2]. Group 1: Lawsuit Details - The lawsuit, Jboor v. Replimune Group, Inc., seeks to represent investors who acquired Replimune securities between November 22, 2024, and July 21, 2025 [1][4]. - The lead plaintiff deadline for the lawsuit is set for September 22, 2025 [4]. Group 2: FDA Rejection and Market Reaction - Replimune's stock price plummeted by 77% on July 22, 2025, after the FDA issued a "complete response letter" rejecting the application for RP1, citing inadequacies in the IGNYTE trial [2][7]. - The FDA's letter indicated that the IGNYTE trial was not well-designed or controlled, leading to concerns about the drug's effectiveness [7][8]. Group 3: Allegations Against Replimune - The complaint alleges that Replimune made false and misleading statements regarding the IGNYTE trial's prospects and failed to disclose that the trial was likely deemed inadequate by the FDA [6][9]. - Replimune had previously portrayed an optimistic outlook for RP1, highlighting its Breakthrough Therapy designation and the potential for durable responses in patients [5][6]. Group 4: Investigation and Whistleblower Information - Hagens Berman is investigating whether Replimune misled investors about the IGNYTE trial design and data, urging affected investors to come forward [3][9]. - Whistleblowers with non-public information regarding Replimune are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [10].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp due to allegations of materially misleading business information [1] Group 1: Legal Actions and Investigations - Shareholders who purchased GeneDx securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - A report by Grizzly Research accused GeneDx of committing widespread fraud, claiming that its growth is an illusion driven by fraudulent schemes [3] Group 2: Stock Performance - Following the allegations from Grizzly Research, GeneDx's stock price fell by $4.84, or 6.7%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 during the Class Period from February 2, 2024, to October 22, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of Alto's common stock during the IPO and the specified Class Period [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 19, 2025, to represent other class members [3]. Group 2: Allegations Against Alto Neuroscience - Defendants allegedly made false statements about ALTO-100's effectiveness in treating major depressive disorder, overstating its clinical and commercial prospects [5]. - The lawsuit claims that Alto's business and financial prospects were also overstated due to these misleading statements [5]. - Investors reportedly suffered damages when the true details about the product and the company's prospects became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements and has a history of successful outcomes for its clients [4].

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a significant decline in share price following the report of a third patient death related to its experimental gene therapy, ELEVIDYS, leading to a 36% drop in stock value on July 18, 2025 [1]. Legal Developments - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, alleging that the company misled investors about the therapy's safety and potential for broader application [4]. Safety Concerns - The complaint highlights that Sarepta failed to disclose critical information regarding the safety of ELEVIDYS, with the first indication of issues arising on March 18, 2025, when a patient death was reported [5]. - Subsequent disclosures included a second patient death on June 15, 2025, and a safety communication from the FDA on June 24, 2025, which investigated the risk of acute liver failure associated with ELEVIDYS [7][8]. Regulatory Actions - Following the reported deaths, the FDA placed Sarepta's clinical trials for both ELEVIDYS and another investigational gene therapy, SRP-9004, on clinical hold [10]. - The company faced increased regulatory scrutiny and was compelled to halt patient recruitment and dosing in its clinical studies due to the severity of adverse events [8]. Financial Impact - The financial press reported a drastic reduction in Sarepta's price target to $0 by H.C. Wainwright following the adverse developments [10].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of KBR, Inc. due to allegations of materially misleading business information issued by KBR [1] Group 1: Investigation and Allegations - The investigation is prompted by KBR's announcement regarding the termination of HomeSafe Alliance's role in a significant contract with U.S. Transportation Command, which led to a notable decline in KBR's stock price [3] - KBR's stock fell by $3.85 per share, or 7.2%, closing at $48.93 on June 20, 2025, following the announcement [3] Group 2: Class Action Details - Shareholders who purchased KBR securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2] - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to secure a Biologics License Application (BLA) for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until September 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Group 1 - The Rosen Law Firm is reminding investors who purchased 3D Systems Corporation securities between August 13, 2024, and May 12, 2025, of the August 12, 2025, lead plaintiff deadline for a class action lawsuit [1][2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [2][5] Group 2 - The lawsuit alleges that during the class period, 3D Systems made false and misleading statements regarding its business resilience and the impact of weakened customer spending [4] - It is claimed that the updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [4] - The lawsuit asserts that these misleading public statements resulted in investor damages when the true information became public [4] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on July 21, 2025 [1] Group 1: Class Action Details - Investors who purchased DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3] - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4] Group 2: Allegations Against DoubleVerify - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5] - It is claimed that DoubleVerify's high-margin Activation Services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5] - The lawsuit also states that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and its risk disclosures were materially misleading [5]

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged misleading statements regarding its drug candidates, potentially impacting investors who purchased securities during the specified period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to purchasers of Biohaven securities between March 24, 2023, and May 14, 2025 [1]. - Allegations include overstated regulatory prospects for the drug troriluzole and its efficacy for treating spinocerebellar ataxia and bipolar disorder, which may have negatively affected Biohaven's business and financial condition [5]. Group 2: Investor Information - Investors who purchased Biohaven securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Viewpoint - A securities class action lawsuit has been filed against XPLR Infrastructure, LP, alleging misleading statements and omissions regarding the company's financial condition and business model during the class period from September 27, 2023, to January 27, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed by Scott+Scott Attorneys at Law LLP in the U.S. District Court for the Southern District of California [1]. - The class action asserts claims under the Securities Exchange Act of 1934 and SEC Rule 10b-5 on behalf of all individuals who purchased XPLR common units during the specified class period [1]. - The case is titled James Alvrus v. XPLR Infrastructure, LP, et al., Case No. 3:25-cv-01755 [1]. Group 2: Allegations Against XPLR - Defendants allegedly made misleading statements about XPLR's operations as a yieldco, failing to disclose struggles in maintaining operations [3]. - The lawsuit claims that XPLR entered into financing arrangements to temporarily alleviate operational issues while downplaying associated risks [3]. - It is alleged that XPLR could not resolve these financings before maturity without risking significant unitholder dilution, leading to a planned halt in cash distributions to investors [3]. - The lawsuit contends that the yieldco business model and distribution growth rate were unsustainable, rendering the defendants' public statements materially false and misleading [3]. Group 3: Market Reaction - On January 28, 2025, XPLR announced a suspension of cash distributions to common unitholders and a shift away from its yieldco model, which shocked investors [4]. - Following this announcement, XPLR's common unit price fell from $15.80 on January 27, 2025, to $10.49 on January 29, 2025, marking a decline of $5.31 per unit, or nearly 35% [4].